尼妥珠单抗联合紫杉醇脂质体、顺铂同步放化疗治疗晚期食管癌的效果

The effect observation of nimotuzumab combined with concurrent chemoradiotherapy in the treatment of advanced esophageal carcinoma

目的观察尼妥珠单抗联合紫杉醇脂质体、顺铂同步放化疗治疗晚期食管癌的疗效和安全性。方法选取2014年2月至2017年4月郑州大学第一附属医院收治的78例晚期食管鳞癌患者,根据治疗方案分为观察组和对照组,各39例。对照组接受紫杉醇脂质体、顺铂方案化疗联合放疗,每3周为1个疗程,观察组在对照组基础上每周接受1次尼妥珠单抗治疗,观察两组的治疗效果和不良反应。结果观察组和对照组的客观缓解率(ORR)分别为51.28%和20.51%,中位生存期(mOS)分别为24.7、17.0个月,中位无进展生存期(mPFS)分别为17.2、9.1个月,差异有统计学意义(均P<0.05)。观察组的不良反应发生情况与对照组比较,差异无统计学意义(P>0.05)。结论晚期食管癌患者行尼妥珠单抗联合紫杉醇脂质体和顺铂同步放化疗治疗有一定效果,可延长患者的PFS和OS,不良反应可耐受,值得在临床中推广应用。

Objective To observe the efficacy and safety of nimotuzumab combined with concurrent chemoradiotherapy(paclitaxel liposomes and cisplatin) in the treatment of advanced esophageal cancer.Methods Seventy-eight patients with advanced esophageal squamous cell carcinoma in the First Affiliated Hospital of Zhengzhou University from February 2014 to April 2017 were selected and divided into observation group and control group according to the treatment regimen, with 39 cases in each group. In the control group,patients were given chemotherapy(paclitaxel liposome, cisplatin) combined radiotherapy, repeat cycle every 3 weeks. In the observation group, patients were given the same chemoradiotherapy as in the control group, and were treated nimotuzumab weekly. The therapeutic effect and adverse reactions between the two groups were calculated and compared during the treatment.Results The objective response rate(ORR) of the observation group and the control group were 51.28% and 20.51% respectively, the median overall survival(mOS) were 24.7 and 17.0 months, and the median progression free survival(mPFS) were 17.2 and 9.1 months, and the differences were statistically significant(all P<0.05). There was no statistically significant difference in adverse reactions between the observation group and the control group(P>0.05).Conclusion Nimotuzumab combined with concurrent chemoradiotherapy in the treatment of advanced esophageal carcinoma has remarkable clinical efficacy, which can significantly prolong the patient’s PFS and OS, the adverse reactions can be tolerated, and is worthy of clinical application.